Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

12.35USD
3:59pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$12.35
Open
$12.35
Day's High
$12.70
Day's Low
$12.35
Volume
12,840
Avg. Vol
15,949
52-wk High
$13.95
52-wk Low
$6.15

Chart for

About

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe... (more)

Overall

Beta: 2.53
Market Cap(Mil.): $129.88
Shares Outstanding(Mil.): 10.52
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

Dec 11 2017

BRIEF-‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​

* ‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:

Nov 09 2017

BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.10

* Eiger Biopharmaceuticals reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Eiger Biopharmaceuticals closes public offering

* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Oct 27 2017

BRIEF-Eiger BioPharmaceuticals announces proposed public offering of common stock

* Eiger BioPharmaceuticals announces proposed public offering of common stock

Oct 26 2017

BRIEF-Eiger appoints Evan Loh to its Board of Directors

* Eiger announces appointment of biopharmaceutical industry veteran Evan Loh, MD to its Board of Directors Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Sphera Funds Management reports 5.35 pct passive stake in Eiger Biopharmaceuticals

* Sphera Funds Management Ltd reports a 5.35 percent passive stake in Eiger Biopharmaceuticals Inc as of August 17, 2017 - SEC Filing​ Source text: (http://bit.ly/2wBB2yX) Further company coverage:

Aug 22 2017

BRIEF-Eiger Biopharmaceuticals Q2 loss per share $1.33

* Eiger Biopharmaceuticals reports second quarter 2017 financial results

Aug 14 2017

BRIEF-Eiger announces FDA fast track designation granted for pegylated interferon lambda

* Eiger announces fda fast track designation granted for pegylated interferon lambda in hepatitis delta virus infection Source text for Eikon: Further company coverage:

Jul 27 2017

Earnings vs. Estimates